The ADMIN-ICU survey: A survey on antimicrobial dosing and monitoring in ICUs

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2671-2677

  Tabah, Alexis ^a,b   de Waele, Jan ^c   Lipman, Jeffrey ^a,b,d   Zahar, Jean Ralph ^e   Cotta, Menino Osbert ^a,b   Barton, Greg ^f,g   Timsit, Jean Francois ^h,i   Roberts, Jason A ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e Unité de Prévention et de Lutte contre les Infections Nosocomiales   (France)

^f ST HELENS AND KNOWSLEY TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^g LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^h BICHAT HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; CONTINUOUS INFUSION; DRUG MONITORING; HEALTH SURVEY; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; PRESCRIPTION; STRUCTURED QUESTIONNAIRE; PROCEDURES; QUESTIONNAIRE;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; INTENSIVE CARE UNITS; SURVEYS AND QUESTIONNAIRES;

EID: 84954287957     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv165     Document Type: Article

References (20)

1. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
2. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
3. Tabah A, Koulenti D, Laupland K et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012; 38: 1930-45.
4. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
5. Udy AA, Baptista JP, Lim NL et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 2014; 42: 520-7.
6. Udy AA, Varghese JM, AltukroniMet al. Subtherapeutic initial b-lactamconcentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
7. Ulldemolins M, Roberts JA, Lipman J et al. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011; 139: 1210-20.
8. Jamal JA, Economou CJ, Lipman J et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18: 460-71.
9. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008; 24: 377-91.
10. Levy MM, Rhodes A, Phillips GS et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 2014; 40: 1623-33.
11. Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
12. Udy AA, Roberts JA, De Waele JJ et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
13. Galvez R, Luengo C, Cornejo R et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38: 146-51.
14. Conil JM, Georges B, Ruiz S et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71.
15. Marik PE, Lipman J, Kobilski S et al. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-64.
16. Touw DJ, Neef C, Thomson AH et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005; 27: 10-7.
17. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-61.
18. Buyle FM, Decruyenaere J, De Waele J et al. A survey of b-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis 2013; 32: 763-8.
19. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
20. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.